ArticlePloS one2012
A human PrM antibody that recognizes a novel cryptic epitope on dengue E glycoprotein.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 27 citations in OpenAlex.
- Article
- Antibody-dependent enhancement (ADE) of dengue virus: Identification of the key amino acid that is vital in DENV vaccine research.The journal of gene medicine · 2021Article
- Adaptive Immunity to Dengue Virus: Slippery Slope or Solid Ground for Rational Vaccine Design?Pathogens (Basel, Switzerland) · 2020Review
- Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice.Frontiers in cellular and infection microbiology · 2020Article
- Viral-Induced Enhanced Disease Illness.Frontiers in microbiology · 2018Review
- Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development.Frontiers in microbiology · 2017Review
- Microbial Cryptotopes are Prominent Targets of B-cell Immunity.Scientific reports · 2016Article
- Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site.Journal of virology · 2016Article
- Fc receptors in antibody-dependent enhancement of viral infections.Immunological reviews · 2015Review
- Replacement of pr gene with Japanese encephalitis virus pr using reverse genetics reduces antibody-dependent enhancement of dengue virus 2 infection.Applied microbiology and biotechnology · 2015Article
- Comprehensive mapping infection-enhancing epitopes of dengue pr protein using polyclonal antibody against prM.Applied microbiology and biotechnology · 2015Article
- Antibodies against immature virions are not a discriminating factor for dengue disease severity.PLoS neglected tropical diseases · 2015Article
- Clinical outcome and genetic differences within a monophyletic Dengue virus type 2 population.PloS one · 2015Article
- The Molecular Engineering of an Anti-Idiotypic Antibody for Pharmacokinetic Analysis of a Fully Human Anti-Infective.PloS one · 2015Article
- Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera.PLoS pathogens · 2014Article
- Mechanism and significance of cell type-dependent neutralization of flaviviruses.Journal of virology · 2014Article
- Development, characterization and application of monoclonal antibodies against Brazilian Dengue virus isolates.PloS one · 2014Article
- Strategies in the development of vaccines to prevent infections with group A streptococcus.Human vaccines & immunotherapeutics · 2013Review
- Identification of a novel infection-enhancing epitope on dengue prM using a dengue cross-reacting monoclonal antibody.BMC microbiology · 2013Article
- Differential targeting of viral components by CD4+ versus CD8+ T lymphocytes in dengue virus infection.Journal of virology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue virus (DENV) is a major mosquito-borne pathogen infecting up to 100 million people each year; so far no effective treatment or vaccines are available. Recently, highly cross-reactive and infection-enhancing pre-membrane (prM)-specific antibodies were found to dominate the anti-DENV immune response in humans, raising concern over vaccine candidates that contain native dengue prM sequences. In this study, we have isolated a broadly cross-reactive prM-specific antibody, D29, during a screen with a non-immunized human Fab-phage library against the four serotypes of DENV. The antibody is capable of restoring the infectivity of virtually non-infectious immature DENV (imDENV) in FcγR-bearing K562 cells. Remarkably, D29 also cross-reacted with a cryptic epitope on the envelope (E) protein located to the DI/DII junction as evidenced by site-directed mutagenesis. This cryptic epitope, while inaccessible to antibody binding in a native virus particle, may become exposed if E is not properly folded. These findings suggest that generation of anti-prM antibodies that enhance DENV infection may not be completely avoided even with immunization strategies employing E protein alone or subunits of E proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.